Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice

Freyn, Alec W., Ramos da Silva, Jamile, Rosado, Victoria C., Bliss, Carly M., Pine, Matthew, Mui, Barbara L., Tam, Ying K., Madden, Thomas D., de Souza Ferreira, Luís Carlos, Weissman, Drew, Krammer, Florian, Coughlan, Lynda, Palese, Peter, Pardi, Norbert and Nachbagauer, Raffael 2020. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Molecular Therapy 28 (7) , pp. 1569-1584. 10.1016/j.ymthe.2020.04.018

Full text not available from this repository.


Influenza viruses are respiratory pathogens of public health concern worldwide with up to 650,000 deaths occurring each year. Seasonal influenza virus vaccines are employed to prevent disease, but with limited effectiveness. Development of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is necessary for reducing influenza virus prevalence. In this study, we have utilized lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccines to intradermally deliver a combination of conserved influenza virus antigens (hemagglutinin stalk, neuraminidase, matrix-2 ion channel, and nucleoprotein) and induce strong immune responses with substantial breadth and potency in a murine model. The immunity conferred by nucleoside-modified mRNA-lipid nanoparticle vaccines provided protection from challenge with pandemic H1N1 virus at 500 times the median lethal dose after administration of a single immunization, and the combination vaccine protected from morbidity at a dose of 50 ng per antigen. The broad protective potential of a single dose of combination vaccine was confirmed by challenge with a panel of group 1 influenza A viruses. These findings support the advancement of nucleoside-modified mRNA-lipid nanoparticle vaccines expressing multiple conserved antigens as universal influenza virus vaccine candidates.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Elsevier (Cell Press)
ISSN: 1525-0016
Date of Acceptance: 14 April 2020
Last Modified: 05 Jan 2021 11:00

Citation Data

Cited 112 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item